Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial
Primary result · Change in ACRResult — go to the resultDifference of change −0.3643 95% CI −0.7571 to 0.0285Authors' conclusion
These results demonstrated that empagliflozin partially suppressed the hypoxia-induced angiogenic factors overproduction in addition to a declining trend in ACR in the early stage of diabetic kidney disease, which might contribute to the mechanisms of reno-protective effects of this agent (jRCTs051200147).
Study context
- Population
- People with T2D and microalbuminuria (early DKD)
- Participants
- 40 vs 39
- Comparison
- Empagliflozin 10 mg/day vs placebo
- Empagliflozinn = 40
- Placebon = 39reference
- Primary endpoint
- Change in urinary albumin creatinine ratio (ACR) and urinary L-FABP excretion
- Follow-up
- Baseline to 24 weeks
Methodological detailsmulticenter, prospective, double blinded, placebo-controlled
- Multicenter
- Prospective
- Double blinded
- Placebo-controlled
Primary result
Change in ACR · 24 weeks
Difference of change
−0.3643
95% CI −0.7571 to 0.0285
P = 0.0686
Empagliflozinvs Placebo
difference of change −0.3643 (95% CI −0.7571 to 0.0285); P = 0.0686
As reported in the abstract
Secondary outcomes
Reduction of albumin creatinine ratio (ACR) · 4 and 12 weeks
- Reduction of ACR significantly greater with empagliflozin than placebo
Serum vascular endothelial growth factor (VEGF), ANGPTL2, ANGPTL4 and adrenomedullin (AM)
- Serum VEGF and ANGPTL2 decreased significantly more with empagliflozin
- No significant differences in AM and ANGPTL4
Original publication
Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial. Diabetes Obes Metab. Published 26 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →